🔍 What This Document Is

This is an 8-K filing with a very important attached contract: a Contingent Value Rights (CVR) Agreement. Think of it as the "extra payment" rules for Hologic's upcoming sale.

Hologic is being acquired by a company called Hopper Parent Inc. As part of that deal, Hologic shareholders won't just get cash upfront. They'll also get a special placeholder called a CVR. This CVR could pay out additional cash in the future if Hologic's business hits certain sales targets after the sale closes.

This agreement spells out exactly how those future payments will be calculated and paid. It's the fine print for a "pay-for-performance" bonus built into the merger.

👉 In simple terms: Hologic's buyers are saying, "We'll pay you $X now, and if we grow the business to $Y in the next two years, we'll pay you up to $3 more per share."

💰 The Deal's Financial Heart: The CVRs

• What are they? CVRs are contractual rights, not actual stock. They can't be traded on the open market (except in very specific family/trust transfers). You hold them, and if conditions are met, you get paid.
• Who gets them? Every Hologic shareholder (and holders of certain stock options/awards) will get one CVR for each share they own when the merger closes.
• What's the max payout? The absolute maximum is $3.00 per CVR, before any taxes. This total is pieced together from three separate potential payments.

🎯 The Milestones: Your Potential $3 Payout

The extra payments are tied to how much revenue Hologic's "Breast Health" business makes. Here are the three separate shots at payment:

1️⃣ Milestone 1 (The 2026 Target)

• The Target: Revenue from Sept. 28, 2025, to Sept. 26, 2026 must hit $1.557 billion.
• The Payout: If they hit $1.557B, you get a base payment. If they grow to $1.572B, you get the full $1.50 per CVR. Payments in between are calculated on a sliding scale ("linear interpolation").
• Key Date: They'll check this around Feb. 23, 2027 (150 days after the period ends).

2️⃣ Milestone 2 (The 2027 Target)

• The Target: Revenue from Sept. 27, 2026, to Sept. 25, 2027 must hit $1.651 billion.
• The Payout: If they hit $1.651B, you get a base payment. If they grow to $1.666B, you get another full $1.50 per CVR. Again, a sliding scale applies.
• Key Date: They'll check this around Feb. 8, 2028 (135 days after the period ends).

3️⃣ The "Catch-Up" Milestone (The Safety Net)

This is a backup plan. Let's say they missed the 2026 target but beat the 2027 target by a lot.

• The Trigger: If 2027 revenue is over $1.666B, they look back at the combined performance of both years.
• The Payout: If the two-year total would have hit the 2026 goal, you can get a "catch-up" payment. This tops you up, but you'll never get more than the total $3.00 across all milestones.

📜 Key Rules & "Gotchas"

• Parent's Obligation: The new owner (Parent) must use "Commercially Diligent Efforts" to run the business and hit these targets. They can't just sabotage the sales to avoid paying. But importantly, they are not guaranteed to hit the milestones.
• How You Get Paid: After each milestone period, Parent calculates the revenue. If a target is hit, they deposit the money with a "Rights Agent" (Equiniti Trust Company), who then mails you a check or wires the funds.
• Tax Hit: They will withhold taxes from any payout, just like regular income.
• No Guarantees: The CVRs have no voting rights, pay no dividends, and earn no interest. This is purely a bet on future sales performance.

🔮 Why This Matters: The Buyer's Gamble & Seller's Hope

This structure is a classic negotiating tool. It bridges the gap between what the buyer (Hopper) wants to pay and what the seller (Hologic shareholders) believes the company is worth.

• For the Buyer (Hopper): They get to pay a lower upfront price, shifting some risk to the sellers. They only pay the full premium if they successfully grow the business as planned.
• For the Seller (You, the Shareholder): You get a lower guaranteed cash payment now, but you keep a "piece of the action." If the new owner is successful and grows the Breast Health division as they expect, you get a nice bonus. It aligns everyone's incentives for growth.

⚖️ Strengths & Risks

• 👍 Strength: It provides a clear, contractual path to additional value. Shareholders aren't completely walking away from future growth they helped build. The "catch-up" provision is shareholder-friendly.
• ⚠️ Risk: The payouts are highly uncertain. Revenue targets are aggressive. The buyer's definition of "Commercially Diligent Efforts" gives them significant operational leeway. You are now a creditor with a very specific, performance-based claim, not an owner.

🧠 The Analogy

Imagine you're selling your successful pizza shop. The buyer pays you $800,000 upfront but says, "I think I can grow this. If, over the next two years, your old shop's annual revenue grows from $1 million to over $1.5 million, I'll pay you an extra $300,000 in installments." You agree because you believe in the shop's potential. The CVR agreement is the contract that defines "revenue," the exact targets, and how the buyer will prove it to you.

🧩 Final Takeaway

This filing details the "earn-out" mechanism for Hologic's sale. Shareholders will receive CVRs that could pay up to $3.00 extra per share if the company's Breast Health division hits specific revenue milestones in 2026 and 2027. It turns part of the sale price into a performance bonus tied to the future success of the business under new ownership.